Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data
Date:4/3/2008

igned to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. rhDNase is designed to improve mucus viscosity. Additional data from this trial will be presented by the independent investigator at a forthcoming scientific congress. A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis, is currently enrolling subjects.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au.

1: rhDNase is marketed as Pulmozyme, which is a trade mark of Genentech

Inc.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

Released through:

Australia: Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

About the Trial

The following information is provided in accord with the ASX and AusBiotech Code of Best Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.

Name of Trial DPM - CF-203 (A phase II study with

Bronchitol)

Blinding Status Open label

Placebo Controlled No

Treatment Method

Route Inhalation

Frequency Twice per day

Dose levels 400 mg

Number of Subjects 20 evaluable

Subject Selection Crite
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... New open ... journal serving the international surgical community ... scientific, technical, and medical information products and services, today ... of Surgery Open ( IJS Open ), ... surgery. This peer-reviewed, online-only journal will make significant contributions ...
(Date:8/4/2015)... Aug. 4, 2015  Natera, Inc. (Nasdaq: NTRA ... analysis of circulating cell-free DNA, today announced that it ... 30, 2015 after the market close on August 12, ... at 1:30 p.m. PT (4:30 p.m. ET) to discuss ... Quarter 2015 Results Conference Call  Date: , Wednesday, August ...
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... Aug. 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... for the second quarter 2015 on Monday, August 10, ... Helen Torley , president and chief executive officer, will ... will release financial results for the second quarter 2015. ... the "Investors" section of Halozyme,s corporate website and a ...
Breaking Biology Technology:Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4Natera to Release Second Quarter 2015 Results on August 12, 2015 2FamilyCord Announces Acquisition of LifeLine Cryogenics 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2
... on Global List for Fifth Consecutive Year, ... GENZ ) announced today that scientists have again ... ranking the reputations of biotechnology and,pharmaceutical companies. Genzyme ... the past five years Genzyme has consistently placed ...
... ... Marketing and Sales, and James Carr Promoted To Vice ... in China -, - Details to be Presented at Investor Briefing Today at 12 p.m. Eastern ... Time -, SOUTH SAN FRANCISCO, Calif., Oct. ...
... Rutgers physicist Emil Yuzbashyan has received a Packard Foundation ... research funding for five years. This marks the first ... to a Rutgers University professor. , Yuzbashyan is among ... 50 of the nations top private and public research ...
Cached Biology Technology:Genzyme Recognized by Scientists as a Top Employer 2Genzyme Recognized by Scientists as a Top Employer 3Genzyme Recognized by Scientists as a Top Employer 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... at the National Institute of Standards and Technology (NIST) ... refrigerant fluids with low "global warming potential" (GWP) ... many decades as well as other desirable performance ... most extensive systematic search for a new class of ...
... /PRNewswire-iReach/ -- Global Information Inc is pleased to offer ... conferences around the world. Early Bird registration prices end ... save up to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ... 11, 2013 | San Francisco, California CHI,s ...
... pioneering wildlife ecologist Aldo Leopold was a meticulous taker of ... bench at his Sauk County shack in Depression-era Wisconsin, Leopold ... with the first pre-dawn calls of the indigo bunting or ... songs he heard, when he heard them, and details such ...
Cached Biology News:New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3
... Rabbit polyclonal to JAK2 (phospho Y1007) ... applications). Antigen: ... around the phosphorylation site of tyrosine ... Entrez Gene ID: 3717 ...
... Fixation Buffer, used in conjunction with ... can be used to fix and ... staining of cytokines and other cytoplasmic ... been specially formulated for reducing non-specific ...
Harmful, Irritant, Combustible ,DEPC...
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... amino acid sequence is proprietary)(Peptide available as ... Gene ID: 55693 ...
Biology Products: